746 Participants Needed

IV vs Oral Iron for Anemia during Pregnancy

(IVIDA2 Trial)

Recruiting at 7 trial locations
CW
SF
Overseen BySteven Fein, MD
Age: 18 - 65
Sex: Female
Trial Phase: Phase 3
Sponsor: Women and Infants Hospital of Rhode Island
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This trial tests if giving iron through an IV drip can help pregnant women with severe anemia who can't tolerate oral iron. It aims to see if this method reduces the need for blood transfusions and improves baby development.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

What data supports the effectiveness of the drug Ferric derisomaltose for treating anemia during pregnancy?

Research shows that intravenous iron treatments like ferric derisomaltose can be more effective than oral iron supplements, such as ferrous sulfate, in treating anemia in pregnant women. Studies comparing similar treatments have found that IV iron often works better and faster in increasing iron levels in the body.12345

Is it safe to use IV or oral iron for anemia during pregnancy?

Research shows that both intravenous (IV) iron treatments like ferric derisomaltose and ferric carboxymaltose, as well as oral iron treatments like ferrous sulfate, have been studied for safety in pregnant women with iron deficiency anemia. These studies generally indicate that both forms of iron are safe for use during pregnancy, although specific side effects and tolerability can vary between individuals.12367

How does the drug Ferric derisomaltose differ from other treatments for anemia during pregnancy?

Ferric derisomaltose is given through an IV (intravenous, directly into the vein), which can work faster and be more effective for severe anemia compared to oral iron pills like ferrous sulfate, which are taken by mouth.128910

Research Team

MT

Methodius Tuuli, MD, MPH, MBA

Principal Investigator

Women and Infants Hospital of Rhode Island

Eligibility Criteria

Pregnant women aged 18-45 with moderate-to-severe iron-deficiency anemia, at 24-28 weeks gestation, planning to deliver at a participating hospital. Excluded are those unable to consent or communicate with the team, carrying multiple babies, having certain digestive conditions or sensitivities to iron treatments, and non-iron-related anemias.

Inclusion Criteria

I am a pregnant woman aged 18-45.
Singleton gestation
Plan to deliver at participating hospital
See 2 more

Exclusion Criteria

Planned delivery at a non-study affiliated hospital
I cannot communicate with the study team even with an interpreter.
Inability or unwillingness to provide informed consent
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either a single IV infusion of 1000 mg ferric derisomaltose or oral iron tablets until delivery

Up to delivery
1 visit (in-person) for IV infusion, regular visits for oral iron monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment, including maternal and neonatal outcomes

6 weeks postpartum
Multiple visits (in-person and/or virtual)

Postpartum Monitoring

Monitoring of maternal and neonatal health outcomes, including neurodevelopment assessments

Up to 36 months for neurodevelopment assessments

Treatment Details

Interventions

  • Ferric derisomaltose
  • Ferrous sulfate
Trial Overview This study is testing if IV iron (Ferric derisomaltose) is more effective and cost-efficient than oral iron (Ferrous sulfate) for pregnant women with low hemoglobin and ferritin levels. It's a double-blind trial meaning neither participants nor researchers know who gets which treatment.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: IV IronExperimental Treatment1 Intervention
Participants assigned to the IV iron group will receive a single IV infusion of 1000 mg ferric derisomaltose (Monoferric, Pharmacosmos Therapeutics Inc., Morristown, NJ) in 250 mL given over 20 minutes and daily placebo tablets until delivery.
Group II: Oral IronActive Control1 Intervention
Participants assigned to the oral iron group will receive a single 250 mL IV normal saline infusion given over 20 minutes and 325mg tablets of ferrous sulfate (65 mg of elemental iron) to be taken until delivery.

Ferric derisomaltose is already approved in United States, European Union for the following indications:

๐Ÿ‡บ๐Ÿ‡ธ
Approved in United States as Monoferric for:
  • Iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron
๐Ÿ‡ช๐Ÿ‡บ
Approved in European Union as Monoferric for:
  • Iron deficiency anemia in adult patients with chronic kidney disease when oral iron preparations are ineffective, cannot be used or for whom there is a clinical need for rapid increase in iron stores

Find a Clinic Near You

Who Is Running the Clinical Trial?

Women and Infants Hospital of Rhode Island

Lead Sponsor

Trials
119
Recruited
59,200+

Hasbro Children's Hospital

Collaborator

Trials
5
Recruited
10,100+

University of Michigan

Collaborator

Trials
1,891
Recruited
6,458,000+

Washington University School of Medicine

Collaborator

Trials
2,027
Recruited
2,353,000+

Findings from Research

In a study involving 201 pregnant women with iron deficiency, intravenous (IV) iron treatment resulted in 91% of participants remaining non-anaemic, compared to only 73% in those receiving oral iron, demonstrating a significant advantage for IV iron (p < 0.001).
IV iron not only improved haemoglobin levels more effectively than oral iron over an 18-week period but also led to greater reductions in fatigue and enhancements in quality of life, with similar safety profiles between the two treatments.
Intravenous ferric derisomaltose versus oral iron for persistent iron deficient pregnant women: a randomised controlled trial.Hansen, R., Sommer, VM., Pinborg, A., et al.[2023]
In a randomized controlled trial with 124 pregnant participants, intravenous ferumoxytol significantly increased maternal hemoglobin levels by an average of 1.86 g/dL compared to only 0.79 g/dL with oral ferrous sulfate (P<.0001).
Intravenous ferumoxytol also resulted in greater improvements in iron indices, with significant increases in ferritin and iron levels, indicating it is a more effective treatment for iron-deficiency anemia in pregnancy than oral iron supplements.
Intravenous infusions of ferumoxytol compared to oral ferrous sulfate for the treatment of anemia in pregnancy: a randomized controlled trial.Awomolo, AM., McWhirter, A., Sadler, LC., et al.[2023]
In a study involving 100 pregnant women with iron deficiency anemia, both bovine lactoferrin and ferrous sulfate effectively increased hemoglobin and iron levels after 30 days of treatment, showing similar efficacy.
Bovine lactoferrin was associated with significantly fewer gastrointestinal side effects, such as abdominal pain and constipation, compared to ferrous sulfate, making it a potentially safer option for treating iron deficiency in pregnant women.
Efficacy and tolerability of oral bovine lactoferrin compared to ferrous sulfate in pregnant women with iron deficiency anemia: a prospective controlled randomized study.Nappi, C., Tommaselli, GA., Morra, I., et al.[2014]

References

Intravenous ferric derisomaltose versus oral iron for persistent iron deficient pregnant women: a randomised controlled trial. [2023]
Intravenous infusions of ferumoxytol compared to oral ferrous sulfate for the treatment of anemia in pregnancy: a randomized controlled trial. [2023]
Efficacy and tolerability of oral bovine lactoferrin compared to ferrous sulfate in pregnant women with iron deficiency anemia: a prospective controlled randomized study. [2014]
A randomized controlled trial comparing the efficacy, tolerability, and cost of oral iron preparations in iron-deficiency anemia in pregnancy. [2021]
[The effectiveness of three regimens using ferrous sulfate to treat anemia in pregnant women]. [2019]
Efficacy and safety of ferric carboxymaltose versus ferrous sulfate for iron deficiency anemia during pregnancy: subgroup analysis of Korean women. [2018]
Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP). [2022]
Intravenous iron sucrose v/s oral ferrous fumarate for treatment of anemia in pregnancy. A randomized controlled trial. [2018]
Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route. [2022]
10.United Statespubmed.ncbi.nlm.nih.gov
Randomized Controlled Trial Comparing Ferrous Sulfate and Iron Sucrose in Iron Deficiency Anemia in Pregnancy. [2023]